Kinetic modelling of quantitative proteome data predicts metabolic reprogramming of liver cancer

Abstract

BACKGROUND: Metabolic alterations can serve as targets for diagnosis and cancer therapy. Due to the highly complex regulation of cellular metabolism, definite identification of metabolic pathway alterations remains challenging and requires sophisticated experimentation. METHODS: We applied a comprehensive kinetic model of the central carbon metabolism (CCM) to characterise metabolic reprogramming in murine liver cancer. RESULTS: We show that relative differences of protein abundances of metabolic enzymes obtained by mass spectrometry can be used to assess their maximal velocity values. Model simulations predicted tumour-specific alterations of various components of the CCM, a selected number of which were subsequently verified by in vitro and in vivo experiments. Furthermore, we demonstrate the ability of the kinetic model to identify metabolic pathways whose inhibition results in selective tumour cell killing. CONCLUSIONS: Our systems biology approach establishes that combining cellular experimentation with computer simulations of physiology-based metabolic models enables a comprehensive understanding of deregulated energetics in cancer. We propose that modelling proteomics data from human HCC with our approach will enable an individualised metabolic profiling of tumours and predictions of the efficacy of drug therapies targeting specific metabolic pathways.

Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis

“…With further study, 37 genes closely associated with carcinogensis in T2DM were revealed, and the interactions among them were concentrated on carbohydrate metabolism as well. These findings are consistent with several published studies [ 24 , 25 ], and provide a promising direction for the investigation of the metabolism-related molecules relevant to the development of HCC and progression of T2DM.…”

Metabolic heterogeneity of human hepatocellular carcinoma: implications for personalized pharmacological treatment

“…Therefore, we developed a novel approach that combines proteomic analysis of liver tissue with kinetic modeling of liver metabolism. In a preceding work [28], we demonstrated that this approach is capable of correctly predicting the metabolic phenotype of liver tumors in a mouse model. In this work, we used proteomics data on protein…”

Metabolism and cancer: the future is now

“…In this special issue, several contributions added essential pieces to this puzzle. For instance, Berndt et al 3 capitalise on a unique in silico modelling approach using proteomics data not only to predict metabolic changes in liver cancer, but also to identify metabolic pathways whose inhibition selectively affects cancer cells. In addition, Becker 4 provides an extensive review of the regulation of pH in cancer cells and proposes the concept of a 'transport metabolon', whereby multiple transporters act together to regulate acid/base homoeostasis in cancer cells, a key regulator of cellular metabolism.…”